生命科学资讯

Umoja delays first readout for in vivo CAR-T therapy

Rezolute crashes as its only drug fails in Phase 3

Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trial

Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some

Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test

FDA clears Lumosity brain training games as a prescription app for adult ADHD

Lilly’s three-pronged drug puts obesity field ‘on notice’

Your lab’s new best friend for scalable proteomics: Illumina Protein Prep - Illumina

AC Immune says early biomarker data are promising in Parkinson's, but clinical benefit remains unclear

10x Genomics Shares Slide Amid Downgrade and Insider Selling - TipRanks

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually - marketscreener.com

Corbus’ obesity pill posts muted weight loss data; Disco adds another €16M in seed funding

Citigroup Upgrades Thermo Fisher Scientific (TMO), Raises Price Target | TMO Stock News - GuruFocus

Life on Mars? Proteomic Secrets of Bacterial Survival in Martian Brines

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Newswise - Newswise

Is Waters Corporation Stock Outperforming the Nasdaq? - Yahoo Finance

Is Waters Corporation Stock Outperforming the Nasdaq? - Barchart.com

Illumina (NASDAQ: ILMN) invests in MyOme to launch AI-driven WGS trial in 2026 - Stock Titan

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually - PR Newswire

Observation of Shapiro steps in an ultracold atomic Josephson junction | Science